NEWS & MEDIA
We’re not only at the front lines of therapeutic advancement, we’re also continuously making headlines in healthcare, business, and research markets.
PRESS RELEASES
BeyondSpring Provides Third-Quarter 2019 Operational and Financial Results Update
BeyondSpring Provides Third-Quarter 2019 Operational and Financial Results Update December 18, 2019 Preparing to Submit NDA in China for Chemotherapy-Induced Neutropenia ("CIN") in Q1 2020 / Plinabulin's Anti-Cancer and CIN Prevention Mechanism Published in Peer...
BeyondSpring to Host Third-Quarter 2019 Financial Results and Operational Update Conference Call on December 18, 2019
BeyondSpring to Host Third-Quarter 2019 Financial Results and Operational Update Conference Call on December 18, 2019 December 11,2019 NEW YORK, Dec. 11, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global...
BeyondSpring’s Study 106 Phase 3 Superior Trial Design Combining Plinabulin with Pegfilgrastim Versus Pegfilgrastim Alone for Chemotherapy-Induced Neutropenia Presented at ASH 2019 Annual Meeting
BeyondSpring's Study 106 Phase 3 Superior Trial Design Combining Plinabulin with Pegfilgrastim Versus Pegfilgrastim Alone for Chemotherapy-Induced Neutropenia Presented at ASH 2019 Annual Meeting December 10, 2019 Trial Aims to Optimize Chemotherapy by Minimizing Dose...
BeyondSpring’s Abstracts on Clinical Evidence for Bone Marrow Stem Cell Protection as Plinabulin’s Mechanism of Action for CIN Accepted at American Society of Hematology’s 2019 Annual Meeting
BeyondSpring's Abstracts on Clinical Evidence for Bone Marrow Stem Cell Protection as Plinabulin's Mechanism of Action for CIN Accepted at American Society of Hematology's 2019 Annual Meeting December 9, 2019 Data Suggest Protective Effects of Plinabulin on Bone...
MEDIA
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.